PT-141 (Bremelanotide) Side Effects: Vyleesi Safety Profile
PT-141 is commonly used as a name for bremelanotide. Vyleesi is the FDA-approved bremelanotide product for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), with important limitations: it is not indicated for postmenopausal women or men, and not indicated to enhance sexual performance.
PT-141 is commonly used as a name for bremelanotide. Vyleesi is the FDA-approved bremelanotide product for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), with important limitations: it is not indicated for postmenopausal women or men, and not indicated to enhance sexual performance.
Key Takeaways
- Bremelanotide is approved as Vyleesi for a specific HSDD indication in premenopausal women, not for men, postmenopausal women, or performance enhancement.
- Nausea is very common and led some trial participants to discontinue treatment.
- Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease, it causes a transient blood-pressure increase and heart-rate reduction.
- Do not use more than one dose in 24 hours or more than eight doses per month.
- It can significantly reduce oral naltrexone exposure, avoid oral naltrexone products for alcohol/opioid addiction with Vyleesi.
PT-141 / Bremelanotide at a Glance
| Property | Detail |
|---|---|
| Also known as | Bremelanotide; FDA-approved product Vyleesi |
| Approved indication | Premenopausal women with acquired, generalized HSDD |
| Not indicated for | Postmenopausal women, men, or sexual-performance enhancement |
| Mechanism | Melanocortin receptor agonist |
| Contraindications | Uncontrolled hypertension; known cardiovascular disease |
| Dose limits | Max 1 dose / 24 hours; max 8 doses / month |
| Key interaction | May significantly reduce oral naltrexone exposure |
PT-141 Side Effects: What Is Known
Because bremelanotide is an approved medicine, its adverse-effect profile is label-defined for the Vyleesi indication. Common reactions include nausea, flushing, injection-site reactions, headache, and vomiting.
| Side Effect | Detail | Significance |
|---|---|---|
| Nausea | Very common; can be severe | Led some trial participants to discontinue treatment |
| Blood-pressure / heart-rate changes | Transient BP increase and HR reduction after dosing | Contraindicated in uncontrolled hypertension or known CV disease |
| Flushing & headache | Common | Usually transient but can affect tolerability |
| Injection-site reactions & vomiting | Common | Monitor; report severe or persistent vomiting |
| Focal hyperpigmentation | Darkening of skin/gums | A label warning, more likely with repeated dosing |
| Naltrexone interaction | Reduced oral naltrexone exposure | Avoid oral naltrexone for alcohol/opioid addiction with Vyleesi |
Using PT-141 with other medications?
Check it against your full medication list instantly. Allmeds flags interactions like the naltrexone concern in minutes.
Safety Profile in Detail
| Dimension | Research summary |
|---|---|
| Mechanism | Bremelanotide is a melanocortin receptor agonist. Its therapeutic mechanism in HSDD is not simply peripheral sexual-performance enhancement. |
| Clinical evidence | FDA approval is based on clinical trials for a specific HSDD population, not broad libido, bodybuilding, or performance use. |
| Severity | Moderate, due to blood-pressure effects, nausea, contraindications, and drug interactions. |
| Symptoms to watch | Nausea, flushing, injection-site reactions, headache, vomiting, high blood-pressure symptoms, dizziness, pigmentation changes, or severe vomiting. |
| Official guidance | Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. Warnings include transient BP increase and HR reduction, focal hyperpigmentation, and nausea. |
| Practical patient advice | Do not use more than one dose in 24 hours or more than eight per month. Avoid oral naltrexone products for alcohol/opioid addiction with Vyleesi because exposure may be reduced. |
Common Questions About PT-141 Side Effects
Bremelanotide is approved as Vyleesi for a specific HSDD indication in premenopausal women.
Vyleesi is not indicated for men.
Nausea is very common and led some trial participants to discontinue treatment.
People with uncontrolled hypertension or known cardiovascular disease should not use it.
Yes. It may significantly reduce oral naltrexone exposure; oral naltrexone products for alcohol/opioid addiction should be avoided.
Check PT-141 against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. fda.gov.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). tga.gov.au.
- European Medicines Agency. Product information and EPARs. ema.europa.eu.